{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:36:41Z","timestamp":1792132601595,"version":"4.4.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12072-024-10711-4","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:03:10Z","timestamp":1722949390000},"page":"941-958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier"],"prefix":"10.1007","volume":"18","author":[{"given":"Ashok","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruveena","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0544-5610","authenticated-orcid":false,"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"4","key":"10711_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin SK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353\u2013390","journal-title":"Hepatol Int"},{"issue":"5","key":"10711_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s12072-017-9816-z","volume":"11","author":"A Choudhury","year":"2017","unstructured":"Choudhury A, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461\u2013471","journal-title":"Hepatol Int"},{"issue":"5","key":"10711_CR3","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/hep.30494","volume":"69","author":"N Mahmud","year":"2019","unstructured":"Mahmud N, et al. Incidence and mortality of acute-on-chronic liver failure using two definitions in patients with compensated cirrhosis. Hepatology. 2019;69(5):2150\u20132163","journal-title":"Hepatology"},{"issue":"2","key":"10711_CR4","doi-asserted-by":"publisher","first-page":"e0026","DOI":"10.1097\/HC9.0000000000000026","volume":"7","author":"Y Lan","year":"2023","unstructured":"Lan Y, et al. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2019. Hepatol Commun. 2023;7(2):e0026","journal-title":"Hepatol Commun"},{"issue":"9","key":"10711_CR5","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u20132700","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10711_CR6","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573\u2013e582","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10711_CR7","doi-asserted-by":"publisher","first-page":"e196412","DOI":"10.1001\/jamanetworkopen.2019.6412","volume":"2","author":"ES Orman","year":"2019","unstructured":"Orman ES, et al. Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis. JAMA Netw Open. 2019;2(6):e196412","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10711_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrgastro.2015.219","volume":"13","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol. 2016;13(3):131\u2013149","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10711_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2023.04.021","volume":"79","author":"R Moreau","year":"2023","unstructured":"Moreau R, et al. EASL clinical practice guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79(2):461\u2013491","journal-title":"J Hepatol"},{"issue":"4","key":"10711_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12072-014-9580-2","volume":"8","author":"SK Sarin","year":"2014","unstructured":"Sarin SK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8(4):453\u2013471","journal-title":"Hepatol Int"},{"issue":"12","key":"10711_CR11","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/jgh.13799","volume":"32","author":"A Choudhury","year":"2017","unstructured":"Choudhury A, et al. Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of \u2018golden window\u2019: a prospective study. J Gastroenterol Hepatol. 2017;32(12):1989\u20131997","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10711_CR12","doi-asserted-by":"publisher","first-page":"100176","DOI":"10.1016\/j.jhepr.2020.100176","volume":"3","author":"G Zaccherini","year":"2021","unstructured":"Zaccherini G, Weiss E, Moreau R. Acute-on-chronic liver failure: definitions, pathophysiology and principles of treatment. JHEP Reports. 2021;3(1):100176","journal-title":"JHEP Reports"},{"issue":"12","key":"10711_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11894-016-0535-8","volume":"18","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Choudhury A. Acute-on-chronic liver failure. Curr Gastroenterol Rep. 2016;18(12):61","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10711_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases. Hepatology. 2018;67(1):328\u2013357","journal-title":"Hepatology"},{"issue":"1","key":"10711_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW Wong","year":"2018","unstructured":"Wong VW, et al. Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70\u201385","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10711_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"EASL-EASD-EASO,","year":"2016","unstructured":"EASL-EASD-EASO,. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u20131402","journal-title":"J Hepatol"},{"issue":"5","key":"10711_CR17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.29607","volume":"67","author":"MS Siddiqui","year":"2018","unstructured":"Siddiqui MS, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2018;67(5):2001\u20132012","journal-title":"Hepatology"},{"issue":"7","key":"10711_CR18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1","journal-title":"Gastroenterology"},{"issue":"12","key":"10711_CR19","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018\u20133030","journal-title":"Liver Int"},{"issue":"1","key":"10711_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"3","key":"10711_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"SG Sepanlou","year":"2020","unstructured":"Sepanlou SG, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(3):245\u2013266","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"2","key":"10711_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, et al. Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2020;5(2):167\u2013228","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10711_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim GEH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619-629.e7","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10711_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/lt.25443","volume":"25","author":"P Axley","year":"2019","unstructured":"Axley P, et al. NASH Is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the united states: a population-based study. Liver Transpl. 2019;25(5):695\u2013705","journal-title":"Liver Transpl"},{"issue":"5","key":"10711_CR25","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/hep.31566","volume":"73","author":"V Sundaram","year":"2021","unstructured":"Sundaram V, et al. Acute on chronic liver failure from nonalcoholic fatty liver disease: a growing and aging cohort with rising mortality. Hepatology. 2021;73(5):1932\u20131944","journal-title":"Hepatology"},{"issue":"28","key":"10711_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4254\/wjh.v9.i28.1133","volume":"9","author":"A Selva Rajoo","year":"2017","unstructured":"Selva Rajoo A, et al. Acute-on-chronic liver failure in a multi-ethnic Asian city: a comparison of patients identified by Asia-Pacific association for the study of the liver and european association for the study of the liver definitions. World J Hepatol. 2017;9(28):1133\u20131140","journal-title":"World J Hepatol"},{"issue":"6","key":"10711_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.14309\/ajg.0000000000000201","volume":"114","author":"H Devarbhavi","year":"2019","unstructured":"Devarbhavi H, et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol. 2019;114(6):929\u2013937","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10711_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/1751-2980.12074","volume":"14","author":"A Duseja","year":"2013","unstructured":"Duseja A, et al. APACHE II score is superior to SOFA, CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure (ACLF). J Dig Dis. 2013;14(9):484\u2013490","journal-title":"J Dig Dis"},{"issue":"2","key":"10711_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jceh.2017.11.008","volume":"8","author":"S Kulkarni","year":"2018","unstructured":"Kulkarni S, et al. Acute on chronic liver failure-in-hospital predictors of mortality in ICU. J Clin Exp Hepatol. 2018;8(2):144\u2013155","journal-title":"J Clin Exp Hepatol"},{"issue":"23","key":"10711_CR30","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.3748\/wjg.v27.i23.3372","volume":"27","author":"RM Lai","year":"2021","unstructured":"Lai RM, et al. Effect of type 2 diabetic mellitus in the prognosis of acute-on-chronic liver failure patients in China. World J Gastroenterol. 2021;27(23):3372\u20133385","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10711_CR31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/jgh3.12557","volume":"5","author":"B Valantine","year":"2021","unstructured":"Valantine B, et al. Predictors of early mortality among patients with acute-on-chronic liver failure. JGH Open. 2021;5(6):686\u2013694","journal-title":"JGH Open"},{"issue":"6","key":"10711_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jceh.2019.04.050","volume":"9","author":"A Gawande","year":"2019","unstructured":"Gawande A, et al. Acute-on-chronic liver failure: etiology of chronic and acute precipitating factors and their effect on mortality. J Clin Exp Hepatol. 2019;9(6):699\u2013703","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10711_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12664-015-0574-3","volume":"34","author":"D Amarapurkar","year":"2015","unstructured":"Amarapurkar D, et al. Acute-on-chronic liver failure: a prospective study to determine the clinical profile, outcome, and factors predicting mortality. Indian J Gastroenterol. 2015;34(3):216\u2013224","journal-title":"Indian J Gastroenterol"},{"issue":"1","key":"10711_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/liv.14671","volume":"41","author":"A Duseja","year":"2021","unstructured":"Duseja A, et al. Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failure. Liver Int. 2021;41(1):150\u2013157","journal-title":"Liver Int"},{"issue":"7","key":"10711_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jcma.2015.12.006","volume":"79","author":"NT Wang","year":"2016","unstructured":"Wang NT, et al. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc. 2016;79(7):368\u2013374","journal-title":"J Chin Med Assoc"},{"key":"10711_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12879-016-1344-2","volume":"16","author":"WS Kim","year":"2016","unstructured":"Kim WS, et al. Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10711_CR37","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1097\/QAD.0b013e32814e6b08","volume":"21","author":"CJ Hoffmann","year":"2007","unstructured":"Hoffmann CJ, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21(10):1301\u20131308","journal-title":"AIDS"},{"issue":"6","key":"10711_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1872-034X.2007.00072.x","volume":"37","author":"G Tarantino","year":"2007","unstructured":"Tarantino G, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 2007;37(6):410\u2013415","journal-title":"Hepatol Res"},{"issue":"5","key":"10711_CR39","first-page":"731","volume":"9","author":"TO Kolaric","year":"2021","unstructured":"Kolaric TO, et al. Drug-induced fatty liver disease: pathogenesis and treatment. J Clin Transl Hepatol. 2021;9(5):731\u2013737","journal-title":"J Clin Transl Hepatol"},{"key":"10711_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.apha.2019.01.003","volume":"85","author":"J Allard","year":"2019","unstructured":"Allard J, et al. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Adv Pharmacol. 2019;85:75\u2013107","journal-title":"Adv Pharmacol"},{"issue":"6","key":"10711_CR41","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/hep4.1904","volume":"6","author":"AV Kulkarni","year":"2022","unstructured":"Kulkarni AV, et al. Tinospora cordifolia (Giloy)-induced liver injury during the covid-19 pandemic-multicenter nationwide study from India. Hepatol Commun. 2022;6(6):1289\u20131300","journal-title":"Hepatol Commun"},{"issue":"1","key":"10711_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","volume":"1","author":"N Peleg","year":"2019","unstructured":"Peleg N, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 2019;1(1):9\u201316","journal-title":"JHEP Rep"},{"issue":"8","key":"10711_CR43","doi-asserted-by":"publisher","first-page":"e72049","DOI":"10.1371\/journal.pone.0072049","volume":"8","author":"YL Cheng","year":"2013","unstructured":"Cheng YL, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS ONE. 2013;8(8):e72049","journal-title":"PLoS ONE"},{"issue":"8","key":"10711_CR44","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/ijc.34637","volume":"153","author":"MN Kim","year":"2023","unstructured":"Kim MN, et al. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. Int J Cancer. 2023;153(8):1448\u20131458","journal-title":"Int J Cancer"},{"issue":"7883","key":"10711_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","volume":"599","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova P, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114\u2013119","journal-title":"Nature"},{"issue":"4","key":"10711_CR46","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak LY, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800\u2013806","journal-title":"J Hepatol"},{"issue":"10","key":"10711_CR47","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s10620-014-3180-9","volume":"59","author":"MM Wang","year":"2014","unstructured":"Wang MM, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014;59(10):2571\u20132579","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10711_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","volume":"56","author":"VW Wong","year":"2012","unstructured":"Wong VW, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56(3):533\u2013540","journal-title":"J Hepatol"},{"issue":"3","key":"10711_CR49","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.28917","volume":"65","author":"EJ Joo","year":"2017","unstructured":"Joo EJ, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65(3):828\u2013835","journal-title":"Hepatology"},{"issue":"1","key":"10711_CR50","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41598-023-28351-3","volume":"13","author":"H Lv","year":"2023","unstructured":"Lv H, et al. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection. Sci Rep. 2023;13(1):1388","journal-title":"Sci Rep"},{"issue":"1","key":"10711_CR51","first-page":"128","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, Xie Q. Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis. J Clin Transl Hepatol. 2022;10(1):128\u2013133","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"10711_CR52","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.jfma.2022.07.013","volume":"121","author":"S-C Huang","year":"2022","unstructured":"Huang S-C, Kao J-H. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. J Formos Med Assoc. 2022;121(11):2148\u20132151","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10711_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","volume":"71","author":"HSJ Choi","year":"2020","unstructured":"Choi HSJ, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology. 2020;71(2):539\u2013548","journal-title":"Hepatology"},{"issue":"8","key":"10711_CR54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/apt.12658","volume":"39","author":"GL Wong","year":"2014","unstructured":"Wong GL, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B\u2013a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39(8):883\u2013893","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10711_CR55","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.100350","volume":"3","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3(5):100350","journal-title":"JHEP Rep"},{"issue":"4","key":"10711_CR56","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1007\/s12072-023-10503-2","volume":"17","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044. Hepatol Int. 2023;17(4):1028\u20131044","journal-title":"Hepatol Int"},{"issue":"4","key":"10711_CR57","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer K, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77(4):918\u2013930","journal-title":"J Hepatol"},{"issue":"1","key":"10711_CR58","doi-asserted-by":"publisher","first-page":"16048","DOI":"10.1038\/s41598-022-20124-8","volume":"12","author":"M Sogabe","year":"2022","unstructured":"Sogabe M, et al. Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females. Sci Rep. 2022;12(1):16048","journal-title":"Sci Rep"},{"key":"10711_CR59","doi-asserted-by":"publisher","first-page":"154439","DOI":"10.1016\/j.metabol.2020.154439","volume":"115","author":"J Blomdahl","year":"2021","unstructured":"Blomdahl J, et al. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabolism. 2021;115:154439","journal-title":"Metabolism"},{"issue":"3","key":"10711_CR60","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.32642","volume":"77","author":"LA van Kleef","year":"2023","unstructured":"van Kleef LA, de Knegt RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. Hepatology. 2023;77(3):942\u2013948","journal-title":"Hepatology"},{"issue":"5","key":"10711_CR61","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/apt.13938","volume":"45","author":"S Zhang","year":"2017","unstructured":"Zhang S, et al. Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection. Aliment Pharmacol Ther. 2017;45(5):701\u2013713","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10711_CR62","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/hep.20879","volume":"42","author":"RA DeAngelis","year":"2005","unstructured":"DeAngelis RA, et al. A high-fat diet impairs liver regeneration in C57BL\/6 mice through overexpression of the NF-kappaB inhibitor. IkappaBalpha Hepatology. 2005;42(5):1148\u20131157","journal-title":"IkappaBalpha Hepatology"},{"key":"10711_CR63","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jceh.2023.07.013","volume":"13","author":"A Kumar","year":"2023","unstructured":"Kumar A, et al. Predictive scores for mortality in MAFLD-related acute-on-chronic liver failure (MAFLD-ACLF): development and validation of MAFLD-MELD-Na and MAFLD-AARC Scores. J Clin Exp Hepatol. 2023;13:S3\u2013S4","journal-title":"J Clin Exp Hepatol"},{"issue":"9","key":"10711_CR64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599\u2013612","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10711_CR65","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1097\/MEG.0000000000002599","volume":"35","author":"AA Hitawala","year":"2023","unstructured":"Hitawala AA, et al. Prevalence of autoimmune, cholestatic and nonalcoholic fatty liver disease in celiac disease. Eur J Gastroenterol Hepatol. 2023;35(9):1030\u20131036","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10711_CR66","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000495767","volume":"26","author":"A Ribeiro","year":"2019","unstructured":"Ribeiro A, et al. Fatty liver and autoimmune hepatitis: two forms of liver involvement in lipodystrophies. GE Port J Gastroenterol. 2019;26(5):362\u2013369","journal-title":"GE Port J Gastroenterol"},{"issue":"2","key":"10711_CR67","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jgh3.12046","volume":"2","author":"A Takahashi","year":"2018","unstructured":"Takahashi A, et al. Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open. 2018;2(2):54\u201358","journal-title":"JGH Open"},{"issue":"1","key":"10711_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MCG.0000000000001817","volume":"58","author":"J Strzepka","year":"2024","unstructured":"Strzepka J, et al. Patients with autoimmune hepatitis and nonalcoholic fatty liver disease: characteristics, treatment, and outcomes. J Clin Gastroenterol. 2024;58(1):91\u201397","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10711_CR69","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148\u20131155","journal-title":"J Hepatol"},{"issue":"5","key":"10711_CR70","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","volume":"71","author":"C Rosso","year":"2019","unstructured":"Rosso C, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71(5):1012\u20131021","journal-title":"J Hepatol"},{"issue":"3","key":"10711_CR71","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jhep.2018.04.016","volume":"69","author":"V Sundaram","year":"2018","unstructured":"Sundaram V, et al. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. J Hepatol. 2018;69(3):617\u2013625","journal-title":"J Hepatol"},{"issue":"11\u201312","key":"10711_CR72","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/apt.13426","volume":"42","author":"V Sundaram","year":"2015","unstructured":"Sundaram V, et al. Obesity is independently associated with infection in hospitalised patients with end-stage liver disease. Aliment Pharmacol Ther. 2015;42(11\u201312):1271\u20131280","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10711_CR73","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1097\/TP.0000000000001461","volume":"100","author":"B Schlansky","year":"2016","unstructured":"Schlansky B, et al. Higher mortality and survival benefit in obese patients awaiting liver transplantation. Transplantation. 2016;100(12):2648\u20132655","journal-title":"Transplantation"},{"issue":"6","key":"10711_CR74","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00134-019-05594-1","volume":"45","author":"M Schetz","year":"2019","unstructured":"Schetz M, et al. Obesity in the critically ill: a narrative review. Intensive Care Med. 2019;45(6):757\u2013769","journal-title":"Intensive Care Med"},{"issue":"3","key":"10711_CR75","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s10620-022-07596-4","volume":"68","author":"R Vijayaraghavan","year":"2023","unstructured":"Vijayaraghavan R, et al. Intragastric balloon in obese compensated nonalcoholic steatohepatitis cirrhosis patients is safe and achieves significant weight reduction at 6-months. Dig Dis Sci. 2023;68(3):1035\u20131041","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10711_CR76","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12664-016-0643-2","volume":"35","author":"NS Choudhary","year":"2016","unstructured":"Choudhary NS, et al. Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation. Indian J Gastroenterol. 2016;35(2):113\u2013116","journal-title":"Indian J Gastroenterol"},{"issue":"4","key":"10711_CR77","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/lt.26560","volume":"29","author":"N Tariq","year":"2023","unstructured":"Tariq N, et al. Combined liver transplantation and sleeve gastrectomy: Report of a brief-interval staged approach. Liver Transpl. 2023;29(4):422\u2013430","journal-title":"Liver Transpl"},{"issue":"2","key":"10711_CR78","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/hep.29848","volume":"68","author":"D Zamora-Valdes","year":"2018","unstructured":"Zamora-Valdes D, et al. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology. 2018;68(2):485\u2013495","journal-title":"Hepatology"},{"issue":"1","key":"10711_CR79","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cgh.2020.04.083","volume":"19","author":"E Vilar-Gomez","year":"2021","unstructured":"Vilar-Gomez E, et al. Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis-related. Child-Pugh A Cirrhosis Clin Gastroenterol Hepatol. 2021;19(1):136-145.e6","journal-title":"Child-Pugh A Cirrhosis Clin Gastroenterol Hepatol"},{"issue":"10","key":"10711_CR80","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","volume":"58","author":"M Stepanova","year":"2013","unstructured":"Stepanova M, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017\u20133023","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10711_CR81","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u20131554","journal-title":"Hepatology"},{"issue":"1","key":"10711_CR82","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2022.09.007","volume":"13","author":"Shalimar,","year":"2023","unstructured":"Shalimar, et al. Incidence and predictors of liver-related events in patients with nonalcoholic fatty liver disease. J Clin Experiment Hepatol. 2023;13(1):37\u201347","journal-title":"J Clin Experiment Hepatol"},{"issue":"9","key":"10711_CR83","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4254\/wjh.v12.i9.533","volume":"12","author":"W Chung","year":"2020","unstructured":"Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol. 2020;12(9):533\u2013557","journal-title":"World J Hepatol"},{"issue":"5","key":"10711_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2021.101272","volume":"47","author":"J Boursier","year":"2021","unstructured":"Boursier J, et al. Management of diabetes mellitus in patients with cirrhosis: an overview and joint statement. Diabetes Metab. 2021;47(5): 101272","journal-title":"Diabetes Metab"},{"issue":"2","key":"10711_CR85","first-page":"e13259","volume":"13","author":"U Farooque","year":"2021","unstructured":"Farooque U, et al. The pattern of dyslipidemia in chronic liver disease patients. Cureus. 2021;13(2):e13259","journal-title":"Cureus"},{"issue":"4","key":"10711_CR86","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis H, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17(4):e1003100","journal-title":"PLoS Med"},{"issue":"1","key":"10711_CR87","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","volume":"116","author":"JI Lee","year":"2021","unstructured":"Lee JI, et al. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Off J Am College Gastroenterol ACG. 2021;116(1):116\u2013124","journal-title":"Off J Am College Gastroenterol ACG"},{"key":"10711_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104392","author":"I Ayada","year":"2023","unstructured":"Ayada I, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104392","journal-title":"EBioMedicine"},{"issue":"8","key":"10711_CR89","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","volume":"59","author":"S Kumar","year":"2014","unstructured":"Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014;59(8):1958\u20131965","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10711_CR90","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"JG Abraldes","year":"2016","unstructured":"Abraldes JG, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160-1170.e3","journal-title":"Gastroenterology"},{"issue":"11","key":"10711_CR91","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","volume":"47","author":"P Pollo-Flores","year":"2015","unstructured":"Pollo-Flores P, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis. 2015;47(11):957\u2013963","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10711_CR92","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12876-019-1147-1","volume":"19","author":"Y Gu","year":"2019","unstructured":"Gu Y, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"10711_CR93","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521-1530.e8","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10711_CR94","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","volume":"5","author":"E Pose","year":"2020","unstructured":"Pose E, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology & Hepatology. 2020;5(1):31\u201341","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"11","key":"10711_CR95","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"JZK Toh","year":"2022","unstructured":"Toh JZK, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(11):2462-2473.e10","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10711_CR96","doi-asserted-by":"publisher","first-page":"e0269265","DOI":"10.1371\/journal.pone.0269265","volume":"17","author":"R Bessho","year":"2022","unstructured":"Bessho R, et al. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS ONE. 2022;17(5):e0269265","journal-title":"PLoS ONE"},{"issue":"4","key":"10711_CR97","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u2013791","journal-title":"Hepatol Int"},{"key":"10711_CR98","doi-asserted-by":"publisher","first-page":"934225","DOI":"10.3389\/fendo.2022.934225","volume":"13","author":"W Wen","year":"2022","unstructured":"Wen W, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2022;13:934225","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10711_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.016","author":"J Quek","year":"2022","unstructured":"Quek J, et al. Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals. Endocr Pract. 2022. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.016","journal-title":"Endocr Pract"},{"issue":"8","key":"10711_CR100","first-page":"e44413","volume":"15","author":"GS Virk","year":"2023","unstructured":"Virk GS, et al. Comparison of outcomes between metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease: a meta-analysis. Cureus. 2023;15(8):e44413","journal-title":"Cureus"},{"issue":"1","key":"10711_CR101","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/TP.0000000000002433","volume":"103","author":"E Tsochatzis","year":"2019","unstructured":"Tsochatzis E, et al. International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation. Transplantation. 2019;103(1):45\u201356","journal-title":"Transplantation"},{"issue":"6","key":"10711_CR102","doi-asserted-by":"publisher","first-page":"100192","DOI":"10.1016\/j.jhepr.2020.100192","volume":"2","author":"P Burra","year":"2020","unstructured":"Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep. 2020;2(6):100192","journal-title":"JHEP Rep"},{"issue":"8","key":"10711_CR103","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/jvh.13287","volume":"27","author":"W Jiang","year":"2020","unstructured":"Jiang W, et al. Prevalence and short-term outcome of acute kidney injury in patients with acute-on-chronic liver failure: a meta-analysis. J Viral Hepatitis. 2020;27(8):810\u2013817","journal-title":"J Viral Hepatitis"},{"issue":"7","key":"10711_CR104","doi-asserted-by":"publisher","first-page":"e1001680","DOI":"10.1371\/journal.pmed.1001680","volume":"11","author":"G Musso","year":"2014","unstructured":"Musso G, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680","journal-title":"PLoS Med"},{"issue":"5","key":"10711_CR105","doi-asserted-by":"publisher","first-page":"102780","DOI":"10.1016\/j.dsx.2023.102780","volume":"17","author":"N Agustanti","year":"2023","unstructured":"Agustanti N, et al. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(5):102780","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10711_CR106","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156\u2013162","journal-title":"Gut"},{"issue":"2","key":"10711_CR107","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/hep.30208","volume":"71","author":"V Arora","year":"2020","unstructured":"Arora V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71(2):600\u2013610","journal-title":"Hepatology"},{"issue":"1","key":"10711_CR108","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/liv.12895","volume":"36","author":"A Jindal","year":"2016","unstructured":"Jindal A, et al. Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure. Liver Int. 2016;36(1):59\u201367","journal-title":"Liver Int"},{"issue":"12","key":"10711_CR109","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1111\/liv.15413","volume":"42","author":"R Maiwall","year":"2022","unstructured":"Maiwall R, et al. Natural history, spectrum and outcome of stage 3 AKI in patients with acute-on-chronic liver failure. Liver Int. 2022;42(12):2800\u20132814","journal-title":"Liver Int"},{"issue":"4","key":"10711_CR110","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u2013238","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10711_CR111","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","volume":"72","author":"A Vitale","year":"2023","unstructured":"Vitale A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITA.LI.CA database. Gut. 2023;72(1):141\u2013152","journal-title":"Gut"},{"issue":"1","key":"10711_CR112","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","volume":"17","author":"M Alexander","year":"2019","unstructured":"Alexander M, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17(1):95","journal-title":"BMC Med"},{"issue":"6","key":"10711_CR113","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/hep.28123","volume":"62","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723\u20131730","journal-title":"Hepatology"},{"issue":"4","key":"10711_CR114","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11901-019-00499-5","volume":"18","author":"OT Ahmed","year":"2019","unstructured":"Ahmed OT, Allen AM. Extrahepatic Malignancies in Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2019;18(4):455\u2013472","journal-title":"Curr Hepatol Rep"},{"key":"10711_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154955","volume":"127","author":"Z Liu","year":"2022","unstructured":"Liu Z, et al. Metabolic dysfunction\u2013associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022;127: 154955","journal-title":"Metabolism"},{"key":"10711_CR116","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/tgh.2020.03.04","volume":"7","author":"JPG Esteban","year":"2022","unstructured":"Esteban JPG, Asgharpour A. Evaluation of liver transplant candidates with non-alcoholic steatohepatitis. Transl Gastroenterol Hepatol. 2022;7:24","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"10","key":"10711_CR117","first-page":"2203","volume":"107","author":"AR Hakeem","year":"2023","unstructured":"Hakeem AR, et al. Preventing small-for-size syndrome in living donor liver transplantation: guidelines from the ILTS-iLDLT-LTSI consensus conference. Transplantation. 2023;107(10):2203\u20132215","journal-title":"Transplantation"},{"issue":"1","key":"10711_CR118","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.dld.2017.08.022","volume":"50","author":"EH van den Berg","year":"2018","unstructured":"van den Berg EH, et al. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis. 2018;50(1):68\u201375","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10711_CR119","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","volume":"71","author":"D Haldar","year":"2019","unstructured":"Haldar D, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European liver transplant registry study. J Hepatol. 2019;71(2):313\u2013322","journal-title":"J Hepatol"},{"key":"10711_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101534","author":"A Minich","year":"2022","unstructured":"Minich A, et al. Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis. eClinicalmedicine. 2022. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101534","journal-title":"eClinicalmedicine"},{"issue":"13","key":"10711_CR121","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.cgh.2019.04.033","volume":"17","author":"S Nagai","year":"2019","unstructured":"Nagai S, et al. Increased risk of death in first year after liver transplantation among patients with nonalcoholic steatohepatitis vs liver disease of other etiologies. Clin Gastroenterol Hepatol. 2019;17(13):2759-2768.e5","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10711_CR122","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.24385","volume":"54","author":"AD Goralczyk","year":"2011","unstructured":"Goralczyk AD, et al. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology. 2011;54(2):541\u2013554","journal-title":"Hepatology"},{"issue":"10","key":"10711_CR123","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4254\/wjh.v7.i10.1355","volume":"7","author":"M Moini","year":"2015","unstructured":"Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol. 2015;7(10):1355\u20131368","journal-title":"World J Hepatol"},{"issue":"3","key":"10711_CR124","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14744\/hf.2023.2023.0032","volume":"4","author":"G Adali","year":"2023","unstructured":"Adali G, et al. Prevalence and predictors of metabolic-associated fatty liver disease in liver transplant recipients: a cross-sectional prospective study. Hepatol Forum. 2023;4(3):129\u2013134","journal-title":"Hepatol Forum"},{"issue":"11","key":"10711_CR125","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1097\/TP.0000000000002916","volume":"103","author":"N Saeed","year":"2019","unstructured":"Saeed N, et al. Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis. Transplantation. 2019;103(11):e345\u2013e354","journal-title":"Transplantation"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10711-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T01:32:34Z","timestamp":1732584754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10711-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":125,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10711"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10711-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}